A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS

(2013) Roger S. McIntyre et al.   DEPRESSION AND ANXIETY

P.1.g.014 Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms

(2013) A. Pehrson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism

(2013) Kristian Gaarn du Jardin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day

(2013) Jean-Philippe Boulenger et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats

(2013) Arne Mørk et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

WHY DO SOME DEPRESSED OUTPATIENTS WHO ARE NOT IN REMISSION ACCORDING TO THE HAMILTON DEPRESSION RATING SCALE NONETHELESS CONSIDER THEMSELVES TO BE IN REMISSION?

(2012) Mark Zimmerman et al.   DEPRESSION AND ANXIETY

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study

(2012) Alan L. Pehrson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder

(2011) Rico S.C. Lee et al.   JOURNAL OF AFFECTIVE DISORDERS

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?

(2011) Anne M. Svendsen et al.   NORDIC JOURNAL OF PSYCHIATRY

Defining and Measuring Functional Recovery from Depression

(2010) Tracy L. Greer et al.   CNS DRUGS

Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder

(2010) James W. Murrough et al.   PSYCHOPHARMACOLOGY

Mediators of the association between depression and role functioning

(2008) M. A. Buist-Bouwman et al.   ACTA PSYCHIATRICA SCANDINAVICA

Remission in depressed outpatients: More than just symptom resolution?

(2007) Mark Zimmerman et al.   JOURNAL OF PSYCHIATRIC RESEARCH